RTY-406 demonstrates significant improvements in disease relevant endpoints in a mouse model of primary sclerosing cholangitis (PSC) and proof of mechanism in non-human primates ...

“These translational results demonstrate that Rectify’s PFM reduces vascular calcification and kidney injury and improves kidney function through enhancement of ABCC6 function,” said Rajesh Devraj, Ph ...

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and ...